Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. Our platform is built on ground-breaking research in advanced computational approaches and taps into uncharted chemical space to design new molecular structures not found in nature.
Our molecules open the door to a brand-new class of medicine with enhanced drug-like properties. We are harnessing the power of our platform to go after previously impossible targets in an array of indications.
We aim to boldly transform the ability to create new medicines, to leverage computing to make high throughput screening obsolete, and to ultimately cure disease. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners.